3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
33
Lymphoma
25
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Non-Hodgkin
12
Leukemia
9
Hodgkin Disease
9
Burkitt Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Multiple Myeloma
8
Lymphoma, Mantle-Cell
8
Lymphoma, Follicular
8
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
7
Sarcoma
6
Neoplasms
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Triple Negative Breast Neoplasms
5
Neutropenia
5
Lymphoma, B-Cell, Marginal Zone
5
Central Nervous System Neoplasms
5
Urinary Bladder Neoplasms
4
Prostatic Neoplasms
4
Osteosarcoma
4
Lung Neoplasms
4
Waldenstrom Macroglobulinemia
3
Testicular Neoplasms
3
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Neuroblastoma
3
Neoplasm Metastasis
3
Interventions
Etoposide
10
Cisplatin
9
Cyclophosphamide
7
etoposide phosphate
5
Paclitaxel
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
Carboplatin
5
fludarabine
4
Sirolimus
4
Gemcitabine
4
pembrolizumab
3
fludarabine phosphate
3
Sunitinib
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bleomycin
3
Bevacizumab
3
Automobiles
3
tremelimumab
2
sodium thiosulfate
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
durvalumab
2
Vorinostat
2
Stem Cell Transplantation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Clear all
NCT02582697
2025-06-15
P3BEP
University of Sydney
Phase 3
Recruiting
500 enrolled
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled